ANNUAL REPORTS
ANNUAL REPORTS

Our Science

Arbele is positioned to be a leader in cancer immunotherapies for solid tumors. A central player in cancer immunotherapy is a type of white blood cell known as the T cell. In healthy individuals, T cells identify and kill infected or abnormal cells like tumors. However, cancer cells carrying the ability (especially in solid tumors) to evade immune surveillance is a key factor in their growth, spread, and persistence. We leverage two technologies - Chimeric Antigen Receptor (CAR) and Bi-specific Monoclonal Antibodies (BiMAbs) - to activate the patient's T cells so that they attack cancer cells.

READ MORE